GLP-1 Agonist Approved (outside US)

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176

A dual GIP/GLP-1 receptor agonist delivering up to 22.5% body weight loss in clinical trials — the most effective weight management peptide available today.

Popularity A+
Class Dual GIP/GLP-1 Receptor Agonist
Half-Life ~5 days
Form Pre-filled pen, Lyophilized powder
Tirzepatide C225H348N48O68
Research-Backed User Reports Sourced Updated Mar 2026
// Overview

What is Tirzepatide?

Tirzepatide (brand name Mounjaro/Zepbound) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed by Eli Lilly for type 2 diabetes management, it has demonstrated unprecedented weight loss results in clinical trials.

In the SURMOUNT-1 trial, participants receiving the highest dose of tirzepatide achieved an average weight loss of 22.5% of body weight over 72 weeks — significantly outperforming semaglutide and other GLP-1 agonists. The dual-agonist mechanism provides synergistic effects on appetite suppression, insulin sensitivity, and metabolic regulation.

Tirzepatide works by simultaneously activating both GIP and GLP-1 receptors, which enhances satiety signaling in the brain, slows gastric emptying, and improves pancreatic beta-cell function. This dual action is thought to be responsible for its superior efficacy compared to GLP-1-only drugs.

Looking for the best vendor deals?

Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.

Compare Vendors
// How It Works

How Tirzepatide Works

Tirzepatide activates both GIP and GLP-1 receptors simultaneously, producing synergistic metabolic effects:

  1. GLP-1 receptor activation slows gastric emptying, reduces appetite via hypothalamic signaling, and enhances glucose-dependent insulin secretion from pancreatic beta cells.
  2. GIP receptor activation enhances fat metabolism, improves lipid profiles, and amplifies the insulinotropic effects of GLP-1. GIP signaling also appears to reduce GLP-1-related nausea over time.
  3. The dual mechanism produces greater weight loss than GLP-1-only agonists, with improved insulin sensitivity and cardiovascular risk markers.
// Dosage Protocols

Dosage Information (User-Reported)

Disclaimer: Dosage information is compiled from user reports and published research. This is not medical advice. Consult a healthcare professional before use.
Level Dose Frequency Duration
Starter 2.5 mg Once weekly 4 weeks
Low 5 mg Once weekly 4+ weeks
Medium 10 mg Once weekly Ongoing
High 15 mg Once weekly Ongoing

What to Expect

Week 1-4

Appetite begins decreasing. Mild nausea possible during titration at 2.5mg. Most report reduced food noise within first 2 weeks.

Week 5-8

Significant appetite suppression at 5mg. Average 5-8% body weight loss. GI side effects typically improving.

Month 3-6

Steady 1-2 lbs/week loss at therapeutic doses. Energy levels stabilize. Improved fasting glucose and lipid panels.

Month 6-12

Peak weight loss phase. Users at 10-15mg report 15-22% total body weight reduction. Muscle preservation requires resistance training.

Common Stacks

BPC-157

GI Protection

Helps mitigate GI side effects common with GLP-1 agonists — nausea, acid reflux

L-Carnitine

Fat Oxidation

Enhances fatty acid transport into mitochondria during accelerated fat loss

Creatine Monohydrate

Muscle Preservation

Counteracts potential lean mass loss during rapid weight reduction

// Preparation

Reconstitution & Storage

If using lyophilized powder: Reconstitute with bacteriostatic water (BAC water). Add water slowly down the side of the vial — do not shake. Gently swirl until fully dissolved. Use within 28 days when refrigerated.

Storage: Refrigerate 2-8°C. Do not freeze. Protect from light.

Ready to source Tirzepatide?

Compare prices across verified vendors. Find the best purity at the lowest price.

Compare Vendors →
// Safety Profile

Side Effects & Safety

Potential Side Effects

  • ! Nausea (most common, typically dose-dependent and transient)
  • ! Diarrhea or constipation
  • ! Decreased appetite (therapeutic effect but can be excessive)
  • ! Injection site reactions
  • ! Gastroesophageal reflux
  • ! Fatigue during initial titration
  • ! Potential gallbladder issues with rapid weight loss
  • ! Pancreatitis (rare but serious — seek immediate care)

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • History of pancreatitis
  • Pregnancy or breastfeeding
  • Severe gastrointestinal disease
// Research

Published Research

// Where to Buy

Top Vendors for Tirzepatide

Ranked by our review scores. All vendors are independently tested.

// Related Compounds

Other GLP-1 Agonist Guides

Cagrilintide

A long-acting amylin analog that amplifies weight loss when paired with semaglutide — the amylin component of CagriSema's…

Read Guide →

BPC-157 Arginate (Oral)

The oral form of BPC-157 — gastric-acid stable and designed for direct GI tract healing. No injections needed…

Read Guide →

TB-500 Fragment

A concentrated fragment of Thymosin Beta-4 focused on the core actin-binding domain — smaller molecule, targeted tissue repair.

Read Guide →

Stay informed on Tirzepatide.

New research, dosage updates, and vendor deals. Straight to your inbox.

Free forever. No spam. Unsubscribe anytime.

This content is for informational and educational purposes only. Tirzepatide is sold for research purposes. Never Natty does not condone or encourage the use of any substance in violation of any laws. Consult a healthcare professional before using any compound discussed on this site.